Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new technique known as optogenetics is lighting up the field of neuroscience. The idea involves genetically engineering neurons to respond to light, and then using powerful lasers to stimulate and control their expression.

A coloured MRI scan of an axial section through the head
A coloured MRI scan of an axial section through the head

The technique holds out the promise of new treatments across a range of previously intractable neurological disorders, from Parkinson's disease to epilepsy. And that promise is already being turned into tangible benefits - if only at this early stage in animal models .

Earlier this month researchers at University College London's Institute of Neurology used optogenetics to suppress epileptic seizures in rats. The study, published in the journal Science, involved inserting a light sensitive gene (taken from a species of algae) into the genetic code of a small population of neural cells associated with focal seizure.

The researchers used a virus to deliver the gene, which expresses the light-sensitive protein halorhodopsin. When they switched on the lights - from a 561-nanometre laser via a fibre-optic cable - the halorhodopsin pumped negatively charged chloride ions into the cell, suppressing activity and making it much harder for the neuron to fire.

"After a fortnight," lead author Dr Robert Wykes says, "the number of seizures dropped dramatically and the animals were effectively cured. It's the first time a gene therapy has been used in combination with optogenetics so its very exciting".

That excitement is shared by the Professor of Neuroscience at Oxford University, Colin Blakemore, who points to optogenetics as one of the key new technologies fuelling a big leap forward in brain science.

"There's no doubt that neuroscience is going through a remarkable purple patch at the moment, and much of that excitement comes from the combination of the knowledge coming from genetics with these new ways of manipulating gene expression in neural cells. That's really marching ahead very fast and it's driving an enormous amount of discovery."

The pioneer of optogenetics, Professor Gero Miesenbock, is now so famous he's been immortalised as a manga comic character and as a children's action figure. "Dr Gero" is a brilliant, but evil, scientist whose skull has been replaced with a plexi-glass dome so that his thoughts can be controlled with light.

"It's exactly what I do," says the real Professor Miesenbock: "optical mind control. But in contrast to my evil twin I don't lust after world domination. I control the brain in order to understand how it works."

Working in fruit flies - whose skulls are thin enough for light to penetrate easily - Professor Miesenbock has been able to identify a number of individual neural cell-types responsible for a range of activities. But as we learn more about the specific function of neurons, he says, we create new opportunities to intervene.

"One can think of many different conditions in which the ability to interfere in the function of specific neural cells could lead to very very powerful new therapeutic avenues."

It is early days, but as the UCL team's work in an animal model of epilepsy shows, optogenetics has enormous potential to deliver new treatments across a wide range of debilitating neurological conditions. It may be years, perhaps decades, before we have the first optogenetic treatment for epilepsy, but Gero Miesenbock is confident there is at least a 561-nanometre laser light at the end of the tunnel.

http://www.bbc.co.uk/news/science-environment-20513292

Similar stories

Mootaz Salman set to target new treatments for stroke

The Chief Scientist Office of the Government of Scotland has awarded a collaborative grant of £298,966 to Dr Mootaz Salman to seek new therapeutic avenues to treat stroke.

New BBSRC grant to further our insights into how the cortex controls sleep

Professor of Sleep Physiology Vladyslav Vyazovskiy and Professor of Developmental Neuroscience Zoltán Molnár have been awarded a Project Grant from the Biotechnology and Biological Sciences Research Council (BBSRC) for “Brain mechanisms of sleep: top-down or bottom-up?”

Raised intracellular chloride levels underlie the effects of tiredness in cortex

A new study, co-authored by Professor Vladyslav Vyazovskiy, published in Nature Neuroscience, has revealed that intracellular chloride levels within cortical pyramidal neurons reflect sleep–wake history.

Key cause of type 2 diabetes uncovered

Research led by Dr Elizabeth Haythorne and Professor Frances Ashcroft reveals high blood glucose reprograms the metabolism of pancreatic beta-cells in diabetes. They have discovered that glucose metabolites, rather than glucose itself, are key to the progression of type 2 diabetes. Glucose metabolites damage pancreatic beta-cell function, so they are unable to release enough of the hormone insulin. Reducing the rate at which glucose is metabolised, and these glucose metabolites build up, can prevent the effects of hyperglycaemia.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.